乳腺癌患者血清丝氨酸蛋白酶抑制剂Kazal 1型、着丝粒蛋白U水平及预后分析  

Analysis of serum serine protease inhibitor Kazal type 1 and centromere protein U levels in breast cancer patients and their prognostic significance

作　　者：李梦丽 李浩田 李鹏 Li Mengli;Li Haotian;Li Peng(Department of General Surgery,the Ninth People's Hospital of Zhengzhou,Zhengzhou,Henan 450053,China.)

机构地区：[1]郑州市第九人民医院普外科,河南郑州450053

出　　处：《齐齐哈尔医学院学报》2024年第17期1641-1646,共6页Journal of Qiqihar Medical University

摘　　要：目的 探讨乳腺癌患者血清丝氨酸蛋白酶抑制剂Kazal 1型(SPINK1)、着丝粒结合蛋白(CENPU)表达水平及其与患者预后的关系。方法 选择2018年8月—2021年8月在本院确诊为乳腺癌的115例患者作为乳腺癌组,并根据2年预后将患者分为预后良好组(92例)与预后不良组(23例);另选择98名同期健康体检者作为对照组。采用ELISA检测血清中SPINK1水平,采用qRT-PCR法检测血清CENPU表达水平;ROC曲线分析血清SPINK1、CENPU水平对乳腺癌患者预后不良的预测价值;Cox回归模型分析乳腺癌患者2年预后的影响因素。结果 乳腺癌患者血清SPINK1、CENPU水平明显高于对照组(P<0.05)。有淋巴结转移、TNM分期Ⅲ期乳腺癌患者血清中SPINK1、CENPU水平明显高于无淋巴结转移、TNM分期Ⅰ+Ⅱ期乳腺癌患者(P<0.05)。预后不良组患者血清SPINK1、CENPU水平高于预后良好组(P<0.05)。ROC曲线分析显示,SPINK1、CENPU预测预后不良的曲线下面积(AUC)分别是0.844(95%CI=0.744~0.943)、0.877(95%CI=0.801~0.953),二者联合预测的AUC为0.946(95%CI=0.899~0.994)。SPINK1、CENPU、淋巴结转移、TNM分期是乳腺癌患者2年内预后不良的独立危险因素(P<0.05)。结论 SPINK1和CENPU水平在乳腺癌患者血清中高表达,是乳腺癌患者预后不良的危险因素,可能作为评估乳腺癌患者预后的标志物。Objective To investigate the expression level of serine protease inhibitor Kazal type 1(SPINK1)and centromere protein U(CENPU)in breast cancer patients and their relationship with patients'prognosis.Methods A total of 115 patients diagnosed with breast cancer in our hospital from August 2018 to August 2021 were selected as the breast cancer group,and were divided into a good prognosis group(92 cases)and a poor prognosis group(23 cases)according to the 2-year prognosis.Another 98 healthy subjects in the same period were selected as the control group.ELISA was applied to detect SPINK1 levels in serum,qRT-PCR method was applied to detect the expression level of serum CENPU;ROC curve was applied to analyze the predictive value of serum SPINK1 and CENPU levels for poor prognosis of breast cancer patients;Cox regression model was applied to analyze the influencing factors of 2-year prognosis of breast cancer patients.Results The serum levels of SPINK1 and CENPU in patients with breast cancer were significantly higher than those in the control group(P<0.05).The serum levels of SPINK1 and CENPU in the breast cancer patients with lymph node metastasis and TNM stageⅢwere obviously higher than those in the breast cancer patients with no lymph node metastasis and TNM stageⅠ+Ⅱ(P<0.05).Serum levels of SPINK1 and CENPU in the poor prognosis group were higher than those in the good prognosis group(P<0.05).ROC curve analysis showed that the area under the curve(AUC)of SPINK1 and CENPU in predicting poor prognosis were 0.844(95%CI=0.744~0.943)and 0.877(95%CI=0.801~0.953),respectively.And the AUC of SPINK1 combined with CENPU in predicting poor prognosis was 0.946(95%CI=0.899~0.994).SPINK1,CENPU,lymph node metastasis and TNM stage were independent risk factors for poor prognosis of breast cancer patients within 2 years(P<0.05).Conclusions SPINK1 and CENPU levels are highly expressed in the serum of breast cancer patients,which are risk factors for poor prognosis of the breast cancer patients,and may be used as markers to eval

关 键 词：乳腺癌 丝氨酸蛋白酶抑制剂Kazal 1型 着丝粒结合蛋白 预后 

分 类 号：R737.9[医药卫生—肿瘤]